Related Experiment Video

Updated: Aug 9, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer

Alain C Mita1, Monica M Mita, Eric K Rowinsky

  • 1Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 4th floor Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, USA. amita@idd.org

Clinical Colorectal Cancer
|August 3, 2004
PubMed

Insights

New targeted therapies show promise for advanced colorectal cancer by interrupting aberrant signal transduction and apoptosis. Further research into these complex systems is needed for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Advanced colorectal cancer treatment outcomes remain poor despite new pharmacologic agents and antibodies.
  • Recent advances in understanding cancer biology and biotechnology are identifying common molecular aberrations in colorectal cancer.
  • This facilitates the development of targeted anticancer agents with potentially lower toxicity and higher efficacy.

Purpose of the Study:

  • To review novel molecular targets and therapeutic agents for advanced colorectal cancer.
  • To discuss agents designed to interrupt aberrant signal transduction and apoptotic processes.
  • To emphasize the complexity of these systems and the need for new clinical development paradigms.

Main Methods:

  • Literature review of recent advancements in colorectal cancer biology and targeted therapies.
  • Discussion of specific molecular targets and rationally designed therapeutic agents.
  • Analysis of the potential impact of these agents on signal transduction and apoptosis.

Main Results:

  • Identification of novel molecular targets common in colorectal cancer.
  • Development of selective, target-based therapeutic agents.
  • Potential for reduced nonspecific toxicity and improved therapeutic indices compared to traditional cytotoxic agents.

Conclusions:

  • Targeted therapies offer a promising new direction for advanced colorectal cancer treatment.
  • Interrupting aberrant signal transduction and apoptotic pathways is a key strategy.
  • A thorough scientific understanding is crucial for developing effective clinical paradigms for these novel agents.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...